Patents by Inventor Michael W. Heartlein

Michael W. Heartlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating Gaucher disease
    Patent number: 11571466
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: February 7, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Francis Daniel, Michael W. Heartlein
  • DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES
    Publication number: 20160367703
    Abstract: This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.
    Type: Application
    Filed: February 3, 2016
    Publication date: December 22, 2016
    Inventors: Kurt von Figura, Bernhard Schmidt, Thomas Dierks, Michael W. Heartlein, Andrea Ballabio, Maria Pia Cosma
  • SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A
    Publication number: 20150306187
    Abstract: The invention relates, in part, to improved methods of administering ?-galactosidase A for the treatment of ?-galactosidase A deficiencies including Fabry disease.
    Type: Application
    Filed: May 1, 2015
    Publication date: October 29, 2015
    Inventors: Lisa Marie Sturk, Justin C. Lamsa, Michael W. Heartlein, Vinh Nguyen, Katherine D. Taylor, Zahra Shahrokh
  • COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE
    Publication number: 20140242061
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 28, 2014
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Peter Francis Daniel, Michael W. Heartlein
  • SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A
    Publication number: 20140037612
    Abstract: The invention relates, in part, to improved methods of administering ?-galactosidase A for the treatment of ?-galactosidase A deficiencies including Fabry disease.
    Type: Application
    Filed: May 24, 2013
    Publication date: February 6, 2014
    Applicant: Shire Human Genetic Therapies Inc.
    Inventors: Lisa Marie Sturk, Justin C. Lamsa, Michael W. Heartlein, Vinh Nguyen, Katherine D. Taylor, Zahra Shahrokh
  • GENE THERAPY FOR SULFATASE DEFICIENCY
    Publication number: 20130172403
    Abstract: This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.
    Type: Application
    Filed: February 27, 2012
    Publication date: July 4, 2013
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Kurt von Figura, Bernhard Schmidt, Thomas Dierks, Michael W. Heartlein, Maria Pia Cosma, Andrea Ballabio
  • DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES
    Publication number: 20130028881
    Abstract: This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.
    Type: Application
    Filed: June 20, 2012
    Publication date: January 31, 2013
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Kurt von Figura, Bernhard Schmidt, Thomas Dierks, Michael W. Heartlein, Andrea Ballabio, Maria Pia Cosma
  • Cell that expresses a sulfatase and a formylglycine generating enzyme
    Patent number: 8227212
    Abstract: This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: July 24, 2012
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Kurt von Figura, Bernhard Schmidt, Thomas Dierks, Michael W. Heartlein, Maria Pia Cosma, Andrea Ballabio
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20110059172
    Abstract: Therapeutic compositions containing therapeutic agents and poly(beta-amino esters) or polymers thereof are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles and microparticles containing polymer/therapeutic agent complexes are also described.
    Type: Application
    Filed: January 28, 2009
    Publication date: March 10, 2011
    Inventors: Arthur Tzianabos, Michael W. Heartlein
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20110052673
    Abstract: Therapeutic compositions containing therapeutic agents and nitrogen-containing lipids are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles, microparticles, and complexes containing lipid/therapeutic agent complexes are also described.
    Type: Application
    Filed: January 28, 2009
    Publication date: March 3, 2011
    Inventors: Arthur Tzianabos, Michael W. Heartlein
  • COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE
    Publication number: 20110027254
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Application
    Filed: July 28, 2010
    Publication date: February 3, 2011
    Inventors: Peter Francis DANIEL, Michael W. Heartlein
  • SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A
    Publication number: 20100291060
    Abstract: The invention relates, in part, to improved methods of administering ?-galactosidase A for the treatment of ?-galactosidase A deficiencies including Fabry disease.
    Type: Application
    Filed: August 28, 2008
    Publication date: November 18, 2010
    Applicant: Shire Human Genetic Therapies, Inc
    Inventors: Lisa Marie Sturk, Justin C. Lamsa, Michael W. Heartlein, Vinh Nguyen, Katherine D. Taylor, Zahra Shahrokh
  • In Vivo Production and Delivery of Erythropoietin or Insulinotropin for Gene Therapy
    Publication number: 20100143314
    Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1 (GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express erythropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.
    Type: Application
    Filed: June 24, 2008
    Publication date: June 10, 2010
    Applicant: Shire Human Genetic Therapies, Inc.
    Inventors: Richard F. Selden, Douglas Treco, Michael W. Heartlein
  • In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
    Patent number: 7410799
    Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1 (GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express erythropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.
    Type: Grant
    Filed: July 7, 2004
    Date of Patent: August 12, 2008
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
  • Chimeric proteins for use in transport of a selected substance into cells
    Patent number: 6858578
    Abstract: Chimeric proteins useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding the chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; mammalian cells, modified to contain DNA encoding the chimeric proteins, which express and, optionally, secrete the chimeric proteins; a method of producing the chimeric proteins; a method of isolating the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric protein, which results in transport of the selected substance into cells.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: February 22, 2005
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Michael W. Heartlein, Jeffrey F. Lemontt, Michael F. Concino
  • In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy
    Patent number: 6846676
    Abstract: The invention provides primary and secondary cells that are transfected with a nucleic acid molecule that encodes erythropoietin, clonal or heterogenous strains of such cells, and methods of producing these cell strains.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: January 25, 2005
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Richard F. Selden, Douglas Treco, Michael W. Heartlein
  • Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
    Publication number: 20040229250
    Abstract: This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.
    Type: Application
    Filed: February 10, 2004
    Publication date: November 18, 2004
    Applicant: Transkaryotic Therapies, Inc.
    Inventors: Kurt von Figura, Bernhard Schmidt, Thomas Dierks, Michael W. Heartlein, Maria Pia Cosma, Andrea Ballabio
  • In vivo protein production and delivery system for gene therapy
    Patent number: 6692737
    Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary and secondary cells are transfected to include exogenous genetic material, methods of producing clonal cell strains or heterogenous cell strains, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: February 17, 2004
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
  • In Vivo production and delivery of insulinotropin for gene therapy
    Patent number: 6670178
    Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP-1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy, in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: December 30, 2003
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
  • Optimized promoter constructs
    Publication number: 20030224477
    Abstract: The invention features constructs and related methods for expression of products in mammalian cells, e.g., human cells. Constructs include a human &ggr;-actin, &bgr;-actin, fibronectin, YY1, or &bgr;-tubulin promoter region operably linked to a heterologous nucleic acid sequence.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 4, 2003
    Inventors: Michael W. Heartlein, Justin Chace Lamsa, Douglas A. Treco, Richard F. Selden, Michael F. Concino, Heidi Kempinski